WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017016463) EGFR INHIBITOR AND PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPH THEREOF, AND USE THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/016463 International Application No.: PCT/CN2016/091591
Publication Date: 02.02.2017 International Filing Date: 25.07.2016
IPC:
C07D 401/14 (2006.01) ,A61K 31/4468 (2006.01) ,A61K 31/506 (2006.01) ,A61P 35/00 (2006.01) ,A61P 37/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
445
Non-condensed piperidines, e.g. piperocaine
4468
having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
Applicants: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.[CN/CN]; No.8, Lane 67, Libing Road, Zhangjiang High-Tech Park, Pudong New Area Shanghai 201203, CN
YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.[CN/CN]; 1 South Yangtze River Road, Gaogang District Taizhou, Jiangsu 225321, CN
Inventors: LAN, Jiong; CN
JIANG, Taotao; CN
LI, Daofei; CN
LIU, Xing; CN
Agent: XU & PARTNERS, LLC.; Room No.106, Building No.1 Universal High-Tech Plaza 958 Zhen Bei Road, Putuo District Shanghai 200333, CN
Priority Data:
201510443673.924.07.2015CN
Title (EN) EGFR INHIBITOR AND PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPH THEREOF, AND USE THEREOF
(FR) INHIBITEUR DE L'EGFR ET SEL PHARMACEUTIQUEMENT ACCEPTABLE ET POLYMORPHE DE CELUI-CI, ET UTILISATION ASSOCIÉE
(ZH) EGFR抑制剂及其药学上可接受的盐和多晶型物及其应用
Abstract:
(EN) Provided is an EGFR inhibitor and a pharmaceutically acceptable salt and a polymorph thereof, and a use thereof. In particular, provided is a polymorph, a pharmaceutically acceptable salt or a prodrug of N-(2-(4-(dimethylamino)piperid-1-yl)-5-(5-fluoro-4-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-ylamino)-4-methoxy phenyl)acrylamide. In addition, also provided are a pharmaceutical composition containing the inhibitor and a use thereof.
(FR) L'invention concerne un inhibiteur de l'EGFR ainsi qu'un sel pharmaceutiquement acceptable et un polymorphe de celui-ci, et une utilisation associée. En particulier, l'invention concerne un polymorphe, un sel pharmaceutiquement acceptable ou un promédicament de N-(2-(4-(diméthylamino)pipérid-1-yl)-5-(5-fluoro-4-(1-méthyl-1H-pyrazol-4-yl)pyrimidin-2-ylamino)-4-méthoxy phényl)acrylamide. En outre, l'invention concerne également une composition pharmaceutique contenant l'inhibiteur et une utilisation associée.
(ZH) 提供了一种EGFR抑制剂及其药学上可接受的盐和多晶型物及其应用。具体地,提供了N-(2-(4-(二甲基氨基)哌啶-1-基)-5-(5-氟-4-(1-甲基-1H-吡唑-4-基)嘧啶-2-基氨基)-4-甲氧基苯基)丙烯酰胺的多晶型物、药学上可接受的盐或前药。此外,还提供了含该抑制剂的药物组合物及其应用。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)